136 related articles for article (PubMed ID: 14563524)
1. Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer.
Bennett CL
Crit Rev Oncol Hematol; 2003 Oct; 48(Suppl):S71-4. PubMed ID: 14563524
[TBL] [Abstract][Full Text] [Related]
2. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making.
Bennett CL; Stinson TJ; Laver JH; Bishop MR; Godwin JE; Tallman MS
Leuk Lymphoma; 2000 Mar; 37(1-2):65-70. PubMed ID: 10721770
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
Calhoun EA; Schumock GT; McKoy JM; Pickard S; Fitzner KA; Heckinger EA; Powell EF; McCaffrey KR; Bennett CL
Pharmacoeconomics; 2005; 23(8):767-75. PubMed ID: 16097839
[TBL] [Abstract][Full Text] [Related]
4. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor.
Nichols CR; Fox EP; Roth BJ; Williams SD; Loehrer PJ; Einhorn LH
J Clin Oncol; 1994 Jun; 12(6):1245-50. PubMed ID: 7515413
[TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.
Barnes G; Pathak A; Schwartzberg L
Adv Ther; 2014 Jul; 31(7):683-95. PubMed ID: 24989316
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
Esser M; Brunner H
Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898
[TBL] [Abstract][Full Text] [Related]
7. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
Pérez Velasco R
J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168
[TBL] [Abstract][Full Text] [Related]
8. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.
Goa KL; Bryson HM
Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867
[TBL] [Abstract][Full Text] [Related]
9. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
10. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.
Chouaid C; Bassinet L; Fuhrman C; Monnet I; Housset B
J Clin Oncol; 1998 Aug; 16(8):2700-7. PubMed ID: 9704720
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH
Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806
[TBL] [Abstract][Full Text] [Related]
12. G-CSF as prophylaxis of febrile neutropenia in SCLC.
Adams JR; Lyman GH; Djubegovic B; Feinglass J; Bennett CL
Expert Opin Pharmacother; 2002 Sep; 3(9):1273-81. PubMed ID: 12186620
[TBL] [Abstract][Full Text] [Related]
13. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
14. G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluation.
Messori A; Trippoli S; Tendi E
J Clin Pharm Ther; 1996 Apr; 21(2):57-63. PubMed ID: 8809640
[TBL] [Abstract][Full Text] [Related]
15. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
16. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
17. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
18. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
[TBL] [Abstract][Full Text] [Related]
19. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial.
Bojke L; Sculpher M; Stephens R; Qian W; Thatcher N; Girling D
Pharmacoeconomics; 2006; 24(5):443-52. PubMed ID: 16706570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
